Aspen Neuroscience chair holds 26,658 common shares
The Hasnain Revocable Trust’s preferred-stock holdings automatically convert into common stock upon completion of Aspen Neuroscience’s initial public offering.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Aspen Neuroscience, Inc.'s Executive Chair Faheem Hasnain reported these holdings as of October 29, 2026: 26,658 common shares directly, plus options for 27,322 shares at $7.71 and 41,489 shares at $5.74. The Hasnain Revocable Trust holds Series A-1, A-2 and C preferred stock representing 14,913, 14,316 and 7,120 common shares, respectively, on an as-converted basis. Each preferred share may convert at the holder's option; in connection with completion of the IPO, the preferred stock automatically converts at a 1-for-9.8821 basis, for no additional consideration.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Hasnain Faheem
Role
Executive Chair
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Series A-1 Convertible Preferred Stock F1, F2 | -- | -- | -- |
| Holding | Series A-2 Convertible Preferred Stock F1, F2 | -- | -- | -- |
| Holding | Series C Convertible Preferred Stock F1, F2 | -- | -- | -- |
| Holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| Holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Holdings:
Series A-1 Convertible Preferred Stock — 14,913 contracts (Indirect, See Footnote 2.);
Series A-2 Convertible Preferred Stock — 14,316 contracts (Indirect, See Footnote 2.);
Series C Convertible Preferred Stock — 7,120 contracts (Indirect, See Footnote 2.);
Stock Option (Right to Buy) — 68,811 contracts (Direct);
Common Stock — 26,658 shares (Direct)
Footnotes (4)
- F1. Pursuant to the Issuer's Amended and Restated Certificate of Incorporation, as amended, each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Preferred Stock will automatically convert on a 1-for-9.8821 basis into shares of Common Stock, for no additional consideration. Share numbers give effect to such conversion. The securities have no expiration date.
- F2. Securities held by the Hasnain Revocable Trust.
- F3. The option was granted on June 16, 2022. The option is fully vested and exercisable.
- F4. The option was granted on November 26, 2025. The shares subject to the option were previously eligible to vest in 48 equal monthly installments beginning on December 20, 2025. In September 2026, the vesting schedule was amended such that the unvested shares subject to the option as of September 25, 2026, shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date.
Key Figures
Direct common stock: 26,658 shares
Series A-1 preferred stock underlying common shares: 14,913 shares
Series A-2 preferred stock underlying common shares: 14,316 shares
+4 more
7 metrics
Direct common stock
26,658 shares
Reported as of October 29, 2026
Series A-1 preferred stock underlying common shares
14,913 shares
Held by the Hasnain Revocable Trust; as-converted basis as of October 29, 2026
Series A-2 preferred stock underlying common shares
14,316 shares
Held by the Hasnain Revocable Trust; as-converted basis as of October 29, 2026
Series C preferred stock underlying common shares
7,120 shares
Held by the Hasnain Revocable Trust; as-converted basis as of October 29, 2026
Option underlying common shares and exercise price
27,322 shares at $7.71 per share
Option expires June 15, 2032
Option underlying common shares and exercise price
41,489 shares at $5.74 per share
Option expires November 25, 2035
Preferred stock conversion ratio
1-for-9.8821 basis
Automatic conversion into common stock in connection with completion of the IPO
Key Terms
Convertible Preferred Stock, automatically convert, fully vested and exercisable, vesting schedule
4 terms
Convertible Preferred Stock financial
"Series A-1 Convertible Preferred Stock"
Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.
automatically convert financial
"will automatically convert on a 1-for-9.8821 basis"
fully vested and exercisable financial
"The option is fully vested and exercisable"
vesting schedule financial
"the vesting schedule was amended"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What holdings did ASPE Executive Chair Faheem Hasnain report?
Faheem Hasnain reported 26,658 common shares directly, options covering 27,322 shares at $7.71 and 41,489 shares at $5.74, and preferred stock held by the Hasnain Revocable Trust representing 14,913 Series A-1, 14,316 Series A-2 and 7,120 Series C common shares on an as-converted basis.
What are the vesting terms for the ASPE option expiring in 2035?
The 41,489-share option, with a $5.74 exercise price and a November 25, 2035 expiration, has unvested shares scheduled to vest in equal monthly installments through November 20, 2031. The schedule was amended in September 2026; vesting is subject to continuous service through each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
